IRS Awards $7M to RNAi, microRNA Firms; Grants Shed Light on Company Pipelines
November 04, 2010
IRS Awards $7M to RNAi, microRNA Firms; Grants Shed Light on Company Pipelines
For instance, Tacere Therapeutics received $488,958 in two grants, the first of which supports development of a new hepatitis C treatment, as well as a previously undisclosed eye-disease program.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Alnylam, Tekmira Shares Regain Lost Ground Heading into 2013
January 24, 2013 / Gene Silencing News - Oligo Drugs Advance in the Clinic in 2012 as Delivery Hurdles are Addressed
January 3, 2013 / Gene Silencing News - IP Update: Recent Patents, Patent Applications Awarded to Alnylam, Marina, UMass, and More
November 8, 2012 / Gene Silencing News - Working to Stay Afloat, Marina Aims to Avoid Becoming Latest RNAi Drug Disappearing Act
October 18, 2012 / Gene Silencing News - IP Update: Recent Patents, Patent Applications Awarded to Opko, Alnylam, Santaris, and More
October 18, 2012 / Gene Silencing News